Caixin
Feb 18, 2022 03:19 PM
OPINION

Opinion: China Has Approved Pfizer’s Covid Drug. What’s Next?

Pfizer’s oral Covid-19 Paxlovid pill was conditionally approved by the National Medical Products Administration of China on Feb. 12.  Photo: The Paper
Pfizer’s oral Covid-19 Paxlovid pill was conditionally approved by the National Medical Products Administration of China on Feb. 12. Photo: The Paper

Pfizer’s oral Covid-19 Paxlovid pill was conditionally approved by the National Medical Products Administration (NMPA) of China on Feb. 12. This is an important step taken by China in its pandemic prevention and control. This undoubtedly sends a positive signal, but there is a long way to go before we can see real effects.

Paxlovid is very effective against Covid-19. According to clinical trials, if high-risk groups — those not vaccinated and having a high risk of being severely affected — are administered with Paxlovid in the early stage, which is within five days after showing symptoms, it will lower the risk of hospitalization or death by nearly 90%.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code